John Militello - 19 May 2026 Form 4 Insider Report for ROCKET PHARMACEUTICALS, INC. (RCKT)

Reporting relationship: Vice President of Finance, Treasurer, Principal Accounting Officer
Issuer ticker: RCKT
Reported as of: 19 May 2026
Net transaction value: -$1,157
SEC form: 4
Accepted by SEC: 21 May 2026, 16:06:03 UTC
Prior SEC filing: 14 May 2026
Next SEC filing: 28 May 2026
Source filing: View source filing
Reporting owner signature: /s/ Martin Wilson, as attorney-in-fact for John Militello

Key filing fact

John Militello filed Form 4 for ROCKET PHARMACEUTICALS, INC. (RCKT) on 21 May 2026.

Key facts

This page summarizes John Militello's Form 4 filing for ROCKET PHARMACEUTICALS, INC. (RCKT).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 21 May 2026, 16:06.

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

CIK 0001662170 Primary reporting owner

Relationship: Vice President of Finance, Treasurer, Principal Accounting Officer
Address: C/O ROCKET PHARMACEUTICALS, INC., 9 CEDARBROOK DRIVE, CRANBURY
Signature: /s/ Martin Wilson, as attorney-in-fact for John Militello
Signature date: 21 May 2026

Shares, units, or other non-derivative securities reported in this filing.

RCKT transaction

Sale

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Explanation of responses 2 footnotes

Footnote F1

Holdings include Restricted Stock Units ("RSUs") that convert to common stock on a one-for-one basis.

Footnote F2

The shares of common stock were sold by the Reporting Person in order to pay tax withholding obligations in connection with the vesting of RSUs.

SEC remarks

Vice President of Finance, Treasurer, Principal Accounting Officer